Daclatasvir and sofosbuvir treatment of decompensated liver disease or post‐liver transplant hepatitis C virus recurrence in patients with advanced liver disease/cirrhosis in a real‐world cohort

We report the findings of an early access program providing treatment for chronic hepatitis C virus infection (any genotype) with daclatasvir and sofosbuvir with/without ribavirin to patients with Child‐Pugh class C cirrhosis or prior liver transplant recipients with recurrent hepatitis C virus infe...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwo, Paul, Fried, Michael W., Reddy, K. Rajender, Soldevila‐Pico, Consuelo, Khemichian, Saro, Darling, Jama, Zamor, Phillippe J., Napoli, Andrew A., Anduze‐Faris, Beatrice, Brown, Robert S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880197/
https://www.ncbi.nlm.nih.gov/pubmed/29619415
http://dx.doi.org/10.1002/hep4.1156

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880197/
https://www.ncbi.nlm.nih.gov/pubmed/29619415
http://dx.doi.org/10.1002/hep4.1156

Ejemplares similares